Results 41 to 50 of about 86,629 (276)

Fluorescence-based proteasome activity profiling [PDF]

, 2012
With the proteasome emerging as a therapeutic target for cancer treatment, accurate tools for monitoring proteasome (inhibitor) activity are in demand.
Berkers, C.R., Jong, A., Ovaa, H., Rodenko, B., Schuurman, K.G.   +4 more
core   +1 more source

Cell density–dependent nuclear‐cytoplasmic shuttling of SETDB1 integrates with Hippo signaling to regulate YAP1‐mediated transcription

FEBS Letters, EarlyView.
At low cell density, SETDB1 and YAP1 accumulate in the nucleus. As cell density increases, the Hippo pathway is gradually activated, and SETDB1 is associated with increased YAP1 phosphorylation. At high cell density, phosphorylated YAP1 is sequestered in the cytoplasm, while SETDB1 becomes polyubiquitinated and degraded by the ubiquitin–proteasome ...
Jaemin Eom, Jaewoong Jang, Jung Sun Park, Yong‐Kook Kang   +3 more
wiley   +1 more source

Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types

Journal of Experimental & Clinical Cancer Research, 2010
Background Survivin is known playing a role in drug resistance. However, its role in bortezomib-mediated inhibition of growth and induction of apoptosis is unclear.
Chanan-Khan Asher A, Calinski Diane, Ling Xiang, Zhou Muxiang, Li Fengzhi   +4 more
doaj   +1 more source

Downregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lung [PDF]

, 2013
Phagocytes not only coordinate acute inflammation and host defense at mucosal sites, but also contribute to tissue damage. Respiratory infection causes a globally significant disease burden and frequently progresses to acute respiratory distress syndrome,
A Cross, A G Rossi, A Planaguma, AE Leitch, AE Leitch, AG Rossi, AL Alessandri, B Dibbert, BM Fournier, C Akgul, C D Lucas, C Haslett, C Nathan, C T Robb, CD Lucas, CN Serhan, D A Dorward, DA Dorward, DA Moulding, DA Moulding, DA Steimer, DJ Wardle, E Abraham, EE McGrath, GL Bannenberg, GS Worthen, H Liu, HG Folkesson, HM Marriott, I Dzhagalov St, I Nicoletti, J A Marwick, J Liang, JS Savill, K C Allen, K Ganeshan, KP Steinberg, L Fialkow, L Santo, M A Tait, MA Matthay, N Chiang, N Fotouhi-Ardakani, N Hirani, O Eickmeier, R Boxio, R Duffin, S Brode, S Fox, S Fox, S Michlewska, SJ Leuenroth, SL Poe, SP Garrison, T Hideshima, T Tanaka, TR Ulich, U Koedel, Y Liu   +58 more
core   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis

Blood Cancer Journal
Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice weekly despite studies demonstrating comparable efficacy and less peripheral neuropathy (PN) with once-weekly bortezomib.
Fieke W. Hoff, Rahul Banerjee, Adeel M. Khan, Georgia McCaughan, Bo Wang, Xiaoliang Wang, James Roose, Larry D. Anderson, Andrew J. Cowan, S. Vincent Rajkumar, Gurbakhash Kaur   +10 more
doaj   +1 more source

The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma [PDF]

, 2008
We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase inhibitor (HDACi), PCI-24781. PCI-24781 was studied alone and combined with bortezomib in Hodgkin lymphoma (L428) and non-Hodgkin's ...
Andrew Evens, Joseph Buggy, Kevin David, Lauren Mauro, Leo Gordon, Mint Sirisawad, Richard Miller, Savita Bhalla, Sheila Prachand, Sriram Balasubramanian   +9 more
core   +1 more source

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Day/night variations of myeloid and lymphoid cell subsets in the murine inguinal lymph node

FEBS Open Bio, EarlyView.
The circadian system is involved in the temporal regulation of the immune system. Our study reveals that two innate immune populations, NKT cells and neutrophils, predominate at the beginning of the day in healthy mice, highlighting how the time of day influences immune responses.
Paula M. Wagner, César G. Prucca, Lucia Boffelli, Virginia A. Piqueras, Silvia G. Correa, Mariana Maccioni, Mario E. Guido   +6 more
wiley   +1 more source